Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 4, 2010, Pages 813-817

  Oguri, Tomoyo ^a   Shimokata, Tomoya ^a   Inada, Megumi ^b   Ito, Isao ^a   Ando, Yuichi ^b   Sasaki, Yasutsuna ^c   Hasegawa, Yoshinori ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

^c SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

Author keywords

Carboplatin; Hemodialysis; Pharmacokinetics; Renal failure

Indexed keywords

CARBOPLATIN; GEMCITABINE; ANTINEOPLASTIC AGENT; PACLITAXEL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PATIENT; CASE REPORT; CHRONIC KIDNEY FAILURE; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG INFUSION; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; JAPANESE; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; OVARY CANCER; PRIORITY JOURNAL; ALGORITHM; HALF LIFE TIME; LUNG TUMOR; METABOLISM; MIDDLE AGED; NEOPLASM; OVARY TUMOR; RENAL REPLACEMENT THERAPY; STATISTICAL MODEL; CALVERT FORMULA; DRUG BLOOD LEVEL; MATHEMATICAL PARAMETERS;

ALGORITHMS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HALF-LIFE; HUMANS; KIDNEY FAILURE, CHRONIC; LUNG NEOPLASMS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASMS; OVARIAN NEOPLASMS; RENAL DIALYSIS;

EID: 78149311481     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1366-1     Document Type: Article

References (18)

1. Pastan S, Bailey J (1998) Dialysis therapy. N Engl J Med 338:1428-1437
2. Verbeeck RK, Musuamba FT (2009) Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol 65:757-773
3. Niikura H, Koizumi T, Ito K et al (2003) Carboplatin-based chemotherapy in patients with gynecological malignancies on long-term hemodialysis. Anticancer Drugs 14:735-738
4. Maisonneuve P, Agodoa L, Gellert R et al (1999) Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 354:93-99
5. Go RS, Adjei AA (1999) Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17:409-422
6. Egorin MJ, Van Echo DA, Tipping SJ et al (1984) Pharmacokinetics and dosage reduction of cis-diammine (1, 1-cyclobutanedicarboxylato) platinum in patients with impaired renal function. Cancer Res 44:5432-5438
7. Chatelut E, Rostaing L, Gualano V et al (1994) Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency. Nephron 66:157-161
8. Jeyabalan N, Hirte HW, Moens F et al (2000) Treatment of advanced ovarian carcinoma with carboplatin and paclitaxel in a patient with renal failure. Int J Gynecol Cancer 10:463-468
9. Inoue A, Saijo Y, Kikuchi T et al (2004) Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis. Ann Oncol 15:51-54
10. Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756
11. Le Roy AF, Wehling ML, Sponseller HL et al (1977) Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med 18:184-191
12. Venook AP, Egorin MJ, Rosner GL et al (2000) Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 18:2780-2787
13. Li YF, Fu S, Hu W et al (2007) Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer 17:739-763
14. Ando Y, Minami H, Saka H et al (1997) Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing. Br J Cancer 76:1067-1071
15. Guchelaar HJ, Richel DJ, van Knapen A et al (1996) Clinical, toxicological and pharmacological aspects of gemcitabine. Cancer Treat Rev 22:15-31
16. Kiani A, Kohne CH, Franz T et al (2003) Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment. Cancer Chemother Pharmacol 51:266-270
17. Tomita M, Kurata H, Aoki Y et al (2001) Pharmacokinetics of paclitaxel and cisplatin in a hemodialysis patient with recurrent ovarian cancer. Anticancer Drugs 12:485-487
18. Woo MH, Gregornik D, Shearer PD et al (1999) Pharmacokinetics of paclitaxel in ananephric patient. Cancer Chemother Pharmacol 43:92-96